Clinical Potential of Mesenchymal Stem Cell-Derived Exosomes in Bone Regeneration
Journal of Clinical Medicine · 29.06.2023 · 12 (13) · 4385
DOI: 10.3390/jcm12134385 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.06.2023. Verfasst von Bárbara Torrecillas-Baena und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Gestión Clínica de Endocrinología y Nutrición-GC17, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universit…. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, CIBER “Fragilidad y Envejecimiento Saludable” (CIBERFES) of “Instituto de Salud Carlos III” (ISCIII).
Abstract (Originalsprache)
Bone metabolism is regulated by osteoblasts, osteoclasts, osteocytes, and stem cells. Pathologies such as osteoporosis, osteoarthritis, osteonecrosis, and traumatic fractures require effective treatments that favor bone formation and regeneration. Among these, cell therapy based on mesenchymal stem cells (MSC) has been proposed. MSC are osteoprogenitors, but their regenerative activity depends in part on their paracrine properties. These are mainly mediated by extracellular vesicle (EV) secretion. EV modulates regenerative processes such as inflammation, angiogenesis, cell proliferation, migration, and differentiation. Thus, MSC-EV are currently an important tool for the development of cell-free therapies in regenerative medicine. This review describes the current knowledge of the effects of MSC-EV in the different phases of bone regeneration. MSC-EV has been used by intravenous injection, directly or in combination with different types of biomaterials, in preclinical models of bone diseases. They have shown great clinical potential in regenerative medicine applied to bone. These findings should be confirmed through standardization of protocols, a better understanding of the mechanisms of action, and appropriate clinical trials. All that will allow the translation of such cell-free therapy to human clinic applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unidad de Gestión Clínica de Endocrinología y Nutrición-GC17, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
- Department Bioquímica y Biología Molecular, Campus Rabanales C6-1-E17, Campus de Excelencia Internacional Agroalimentario (ceiA3), Universidad de Córdoba, 14071 Córdoba, Spain.
- CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), 14004 Córdoba, Spain.
ORCID-Profile: Antonio Casado-Díaz
Förderung
- Instituto de Salud Carlos III
- CIBER “Fragilidad y Envejecimiento Saludable” (CIBERFES) of “Instituto de Salud Carlos III” (ISCIII)
Zitieren
APA
Torrecillas-Baena, B., Pulido-Escribano, V., Dorado, G., Gálvez-Moreno, M. Á., Camacho-Cardenosa, M., & Casado-Díaz, A. (2023). Clinical Potential of Mesenchymal Stem Cell-Derived Exosomes in Bone Regeneration. Journal of Clinical Medicine, 12(13), 4385. https://doi.org/10.3390/jcm12134385
Vancouver
Torrecillas-Baena B, Pulido-Escribano V, Dorado G, Gálvez-Moreno MÁ, Camacho-Cardenosa M, Casado-Díaz A. Clinical Potential of Mesenchymal Stem Cell-Derived Exosomes in Bone Regeneration. Journal of Clinical Medicine. 2023;12(13):4385. doi:10.3390/jcm12134385
BibTeX
@article{TorrecillasBaena2023,
author = {Torrecillas-Baena, Bárbara and Pulido-Escribano, Victoria and Dorado, Gabriel and Gálvez-Moreno, María Ángeles and Camacho-Cardenosa, Marta and Casado-Díaz, Antonio},
title = {Clinical Potential of Mesenchymal Stem Cell-Derived Exosomes in Bone Regeneration},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {13},
pages = {4385},
doi = {10.3390/jcm12134385}
}
EUVIMED